A Watertown biotech says is received a $112 million investment led by the investment firm that manages the assets of the Novo ...

Novo is in a strong financial position to continue its exploration focus on Western Australia and Victoria, with no debt and ...

AvenCell Therapeutics has secured $112 million in series B funds as the Novo Holdings-backed biotech seeks clinical proof ...

AvenCell Therapeutics, Inc. ("AvenCell"), a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies, today announced that it has ...

US clinical-stage biotech AvenCell Therapeutics announced that it has raised $112 million in Series B financing, which was ...

The boom experienced by the weight loss drug market comes as little surprise when considering that almost a third of the ...

Novo’s 2024 Sustainability Report demonstrates that Novo remains committed to sustainability as we execute our exploration ...

Berlin, Germany-based Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines ...

Booster Therapeutics launched today with the support of a $15 million financing led by investors Apollo Health Ventures and ...

Discover Booster Therapeutics' novel 20S proteasome activation approach to neurodegenerative diseases as it launches with $15 ...